Genera’s low false negatives
Wednesday, 15 October, 2008
Pilot clinical trials of Genera Biosystems' [ASX: GBI] new PapType HPV detection test have shown that the test gives improved detection rates of cervical cancer than the market leader test.
Currently Qiagen's Hybrid Capture 2 test (HC2) is the only FDA-approved test for cervical cancer screening.
But in Genera's latest trials, PapType outperformed the HC2 test, returning a false negative rate of seven per cent, compared to a 27 per cent false negative rate with HC2.
Genera believes the results are very encouraging, although they are not yet conclusive.
For example, all the women in the study already had an abnormal pap smear. According to Genera, trials from the general population will need to be conducted before the superiority of PapType can be confirmed.
Five scenarios for the future of Antarctic life
A team of Australian and international researchers have predicted five possible outcomes for how...
Could this biosensor bypass labs with onsite PFAS detection?
La Trobe University has developed a portable biosensor that may allow rapid, onsite detection of...
How a tiny worm changed a decade of scientific thinking
A tiny roundworm has helped University of Queensland scientists rethink the way sensory nerve...
